Roughly 620,000 new cases of lymphoma were diagnosed worldwide, according to the World Cancer Research Fund International’s 2020 report. Survival rates have improved as advances develop in treatment, what is a lyrical poem example such as chimeric antigen receptor-T cell therapy (CAR-T cell therapy).
CAR-T cell therapy is a personalized treatment giving hope to patients diagnosed with various lymphomas.
“Lymphoma in plain terms is essentially a cancer of your immune system,” says Dr. Madiha Iqbal, a Mayo Clinic hematologist and oncologist.
Patients who are newly diagnosed with lymphoma are offered a combination of chemotherapy and antibody-based treatments. But for those who do not respond to two or more lines of such treatments, CAR-T cell therapy may be an option.
“Prior to the advent of CAR-T cell therapy, patients who had failed two lines of chemotherapy had a very poor survival of around six months,” says Dr. Iqbal.
Receiving CAR-T cell therapy can take a few weeks as a patient’s T cells, which normally help fight off infections, are collected and genetically engineered to target lymphoma.
After low-dose chemotherapy, the modified cells are infused back into the patient. These cells can then attack and destroy the lymphoma.
Source: Read Full Article
